Overview
MESO market data
Price History
MESO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.16 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -144.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.88 – $3.31 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.1B · P/B 2.50 · P/S 33.82.
Company News
Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · Aug 14, 2026, 12:06 PM
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product LaunchGlobenewswire Inc · Jul 30, 2026, 11:00 AM
Reported Earlier, Mesoblast Posts Q4 Ryoncil Revenue Of $36M, Full-Year Cash Spend Of $43.8M, And $103M Cash Balance At June 30, 2026Benzinga · Jul 30, 2026, 7:42 AM
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On WednesdayBenzinga · Jul 15, 2026, 1:56 PM
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back PainGlobenewswire Inc · Jul 14, 2026, 11:00 AM
Reported Earlier, Mesoblast Hits 300-Patient Enrollment Milestone In Pivotal Phase 3 CLBP Trial, With Primary Endpoint Powered For 12-Month Pain Reduction ComparisonBenzinga · Jul 14, 2026, 7:53 AM
ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · Jun 26, 2026, 12:10 PM
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItBenzinga · May 22, 2026, 3:15 PM